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Abstract This literature review focuses on the O→C acyl migration of
aryl esters to yield the corresponding 1,3-dicarbonyl products—a reac-
tion known as the Baker–Venkataraman rearrangement—and outlines
their subsequent transformations. The purpose of the review is to high-
light the utility of the rearrangement which provides a key step in the
synthesis of various heterocyclic motifs. The scope of the Baker–
Venkataraman rearrangement is illustrated by way of numerous exam-
ples of its application, and in doing so, the review contains over 100 ref-
erences and covers just over 100 years of the literature, from the first
report of the rearrangement by Auwers in 1910 up to more recent ex-
amples in the past few years.
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1 Introduction
Acyl migrations permeate the chemical literature, yet
most involve heteroatom → heteroatom rearrangements;
for example, instances of such acyl migrations have been
observed on ribonucleoside derivatives,1 glycerol esters,2
during the asymmetric synthesis of β-amino tertiary alco-
hols,3 and on the taxane skeleton,4 amongst many others.5
Such migrations have also been exploited as a prodrug
strategy for the preparation of taxoids6 and HIV-1 protease
inhibitors,7 as well as occurring over increasingly long mo-
lecular distances, such as that seen in a 1,7-O,O′-intramo-
lecular acyl migration,8 and via 13-, 15-, and 16-membered
cyclic transition states.9 Such rearrangement reactions are
powerful tools in organic synthesis because simple, readily
available, suitable primed precursors can give rise to large
structural changes in a single step, or they are able to ex-
ploit the inherent reactivity of a molecule under a certain
set of reaction conditions.10 Whilst heteroatom → sp3-car-
bon acyl migrations are known,11 they are less well known
than their all-heteroatom counterpart. As such, the focus of
this review is the specific rearrangement which sees the O
→ C migration of aromatic acyl groups to sp3-carbons—the
so-called Baker–Venkataraman rearrangement (Scheme
1)—reactions which have received numerous citations in
organic chemistry, especially due to their use in the regio-
selective formation of carbon–carbon bonds.
Scheme 1  The Baker–Venkataraman rearrangement
2 Historical Perspective
In 1910, during his work on coumaranones and 2-hy-
droxycoumarones, Auwers observed that esters of 2-chloro-
2′-hydroxyacetophenone 3 reacted with potassium carbon-
ate to form 2-substituted coumaran-3-ones 5, and it was
suggested that the reaction proceeded through the 1,3-
diketone species 4 (Scheme 2).12
O OH
O
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Later, Venkataraman,13 and independently Baker,14 re-
ported the isolation of a similar 1,3-diketone, 10 (Scheme
3), following the rearrangement of 2′-aroyloxyacetophe-
none 6. Since these early examples,15 the reaction has been
exploited and is now of prime importance in the synthesis
of flavones (11), amongst other heterocyclic ring systems
(see section 4).
3 Mechanism
The currently accepted mechanism of this transforma-
tion can be regarded as an intramolecular Claisen conden-
sation between an acetophenone derivative and a proximal
ester on the aromatic ring. Whilst classical Claisen conden-
sations between a ketone and an ester occur intermolecu-
larly, in the Baker–Venkataraman rearrangement both func-
tionalities are present, typically ortho to each other, on the
same aromatic ring, and thus the reaction occurs intramo-
lecularly (Scheme 3).16 The reaction differs from the classi-
cal intramolecular Claisen (Dieckmann) condensation in
that cyclic products are not formed.
Scheme 3  The mechanism of the Baker–Venkataraman rearrange-
ment (6→10)
Using the example in Scheme 3 as an illustration, in a
typical reaction, base abstraction of one of the α-hydrogens
of the aromatic ketone 6 occurs, which results in the forma-
tion of enolate 7. Intramolecular attack of the enolate oc-
curs onto the ester carbonyl to form the cyclic charged
hemiacetal 8, the tetrahedral intermediate of which subse-
quently collapses to form the more stable phenolate 9,
which is protonated during acid workup to give the 1,3-
diketone Baker–Venkataraman product 10.
In 1933, when studying similar reactions, and attempt-
ing the O-benzylation of 4′-benzoylresacetophenone (12),
Baker observed that an unexpected dibenzoylated product,
14, was formed in 20% yield. Upon further investigation into
its mechanism of formation, a sample of separately pre-
pared 2′,4′-dibenzoylresacetophenone (13) was exposed to
the same reaction conditions, wherein the same product 14
was formed. It was thus postulated that the dibenzoylated
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l.product 13 must have been an intermediate of the attempt-
ed benzylation reaction (presumably through intermolecu-
lar benzoyl transfer under the basic reaction conditions),
and that once formed, the dibenzoylated product 13 must
undergo an O→C acyl migration to provide the observed
product 14 (Scheme 4).14
Scheme 4  An unexpected rearrangement during benzylation
Baker confirmed the generality of this new rearrange-
ment by demonstrating success with a variety of related re-
arrangement precursors (Figure 1): 2′-benzoyloxyace-
tophenone (15), resacetophenone diveratrate (16), gallace-
tophenone tribenzoate (17), cinnamoylresacetophenone
(18) and 2′,4′-dibenzoyloxyphenyl benzyl ketone (19), all of
which were successful substrates in the rearrangement. The
results suggest that the acyl migration only occurs when
there is an ortho-aryloxy group, since it does not occur in
4′-benzoyloxyresacetophenone (20) or in 4′- benzoyloxy-
acetophenone (21).14
Figure 1  Early generality of the rearrangement
Furthermore, in the same year, continued attempts by
Venkataraman et al. to effect the dehydration of 2-acetyl-
naphthalen-1-yl benzoate (22) to 1,4-α-naphthapyrones
revealed that the action of sodium amide on an ethereal
solution of 22 at room temperature, followed by decompo-
sition of the precipitate with acid, gave the Baker–
Venkataraman product, diketone 23, instead (Figure 2).17
Incidentally, in the context of naphthalene scaffolds, it has
also been shown that the Baker–Venkataraman rearrange-
ment can take place across peri-substituted naphthalenes,
such as 24, too.18
Figure 2  Naphthalene scaffolds
Continuing these early efforts, the rearrangement, by
then known as the Baker–Venkataraman rearrangement,
was studied and extended by a number of workers.19–24 The
rearrangement of 2′-aroyloxyacetophenones 25 to 2′-hy-
droxybenzoylmethanes 26 (Scheme 5), in the presence of
basic reagents, is typical.22
Scheme 5  Typical rearrangement conditions
Whilst the 1,3-diketone products depicted throughout
this review generally exist in equilibrium with their enol
tautomers, they are represented here as they were depicted
in the original publication. The reader should be aware of
this equilibrium.
4 Applications: General Routes to Heterocy-
cles
Since this early work, the Baker–Venkataraman rear-
rangement has become an extremely reliable reaction in or-
ganic synthesis allowing for the rapid construction of 1,3-
diketones in high yield, and such compounds are known as
important synthetic intermediates that are widely used as a
route to biologically active heterocycles.
In the context of total synthesis, the rearrangement has
become increasingly more important, particularly as 1,3-
diketone starting materials are becoming more widely uti-
lised. As such, this rearrangement is regarded as one of the
most common methods for synthesising anthracyclins, an-
thrapyrans, benzopyrans, chromones, coumarins, flavones,
flavanones and xanthones, and applications of each class
are outlined below.
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The flavone nucleus is an important scaffold used in the
preparation of pharmaceutical agents, since both natural
and synthetic derivatives are known to be responsible for a
large variety of biological and pharmacological activities,
including antitumour, anti-inflammatory, antiviral, and an-
tioxidant properties.25 The presence of hydroxyl groups in
the flavone skeleton is important for their capacity to act as
antioxidants,26 as exemplified by quercetin (3,3′,4′,5,7-pen-
tahydroxyflavone), a well-known antioxidant and import-
ant compound with wide-ranging biological activities.27
Another important structural feature of the flavone class is
the presence of a 3-aroyl group; in fact it has been reported
that flavones bearing this substituent possess antibacterial,
antifungal, and antimalarial activities,28–30 whilst more re-
cently, it has been reported that certain 3-aroylflavones
possess tubulin binding activity as well.31
The first application of the Baker–Venkataraman rear-
rangement towards the synthesis of flavones was by
Venkataraman himself, when he attempted the synthesis of
α-naphthaflavone 27 from naphthyl derivative 22 (Scheme
6).17
Scheme 6  Synthesis of flavones
Subsequently, a variety of flavones have been synthe-
sized which exploit the rearrangement. For example, nine
aroyl-5-hydroxyflavones have been synthesized under a
microwave-assisted Baker–Venkataraman transposition
(Scheme 7).32
In their work, a new and successful method was estab-
lished wherein microwave irradiation was shown to selec-
tively induce a Baker–Venkataraman rearrangement of
2′,6′-diaroyloxyacetophenones 29 to give the corresponding
3-aroyl-5-hydroxyflavones 30, in very short reaction times
(10 min) and good yields (68–72%). Conversely, under clas-
sical thermal conditions these reactions afforded 5-hy-
droxyflavones 30 only as by-products.32
The scope of the reaction was determined and extended
to include other derivatives. For example, the use of 2′,6′-di-
aroyloxyacetophenones with strong electron-withdrawing
substituents in the aromatic ring of the aroyl groups, exem-
plified by the rearrangement of 2′,6′-diaroyloxyaceto-
phenones 29 (R2 = NO2) under their preferred microwave
experimental conditions, led to 3-aroyl-5-hydroxyflavones
30 (R2 = NO2) in good yield.32
In addition, a practical and economical method has
been developed by Brown and co-workers for the synthesis
of eleven flavonoid derivatives (compounds 33) from
2′-hydroxyacetophenones 31 using a modified Baker–
Venkataraman rearrangement, followed by microwave-
assisted condensation of the diones 32 to close the hetero-
cycle.33 All of the synthetic flavonoids displayed antifungal
activity against Aspergillus niger and Fusarium oxysporium,
and two of the analogues exhibited significant activity
against methicillin-resistant Staphylococcus aureus.33
OPh
O
O
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O
O27
reagents
via Baker–Venkataraman
product 23
Scheme 7  The Baker–Venkataraman rearrangement under classical thermal and microwave conditions
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groups at position 5 or 7 is frequently required for satisfac-
tory biological activity to exist,34,35 whilst the analogous
aminoflavones are known tyrosine kinase inhibitors36 and
antimitotic agents.37 In light of this, interest in the synthesis
of flavones bearing both hydroxyl and amino groups began
to grow (Scheme 8). For example, the synthesis of flavone
37 by a modified Baker–Venkataraman method was report-
ed.38 In this process, the 1,3-diketone intermediate 36 was
apparently prepared in one step by the reaction of 34 and
benzoyl chloride using lithium bis(trimethylsilyl)amide
(LiHMDS) as base, at low temperature (–78 °С), but com-
pound 36 was neither isolated nor fully characterised. In an
effort to avoid the inconvenient low temperature prepara-
tion of the 1,3-diketone, the rearrangement was reinvesti-
gated,39 and the synthesis of 35 was achieved from 2′,4′-di-
hydroxy-5′-nitroacetophenone (34) using benzoyl chloride
in refluxing dry acetone in the presence of anhydrous po-
tassium carbonate (Scheme 8). Under these conditions,
yields of the separated compounds, 3-benzoyl-7-hydroxy-
6-nitroflavone (35) and 1-(2,4-dihydroxy-5-nitrophenyl)-
3-phenylpropane-1,3-dione (36), were 43% and 13%, re-
spectively.39
Scheme 8  The Baker–Venkataraman rearrangement applied to the 
synthesis of aminoflavones
These improved results also demonstrated that the hy-
droxyl group para to the ketone in 34 is not acylated under
the selected reaction conditions; this lack of reactivity can
be attributed to resonance deactivation caused by the
ortho-nitro group and para-ketone.
In a similar manner, Ares et al. developed a convenient,
large-scale preparation of 5-methoxyflavone (40; R1 = 5-
OMe, R2 = H) using potassium tert-butoxide, via diketone
39, as the key step (Scheme 9, top), and the method was
successfully applied to the synthesis of a number of further
flavone analogues.40
During their studies it was found that the conventional
Baker–Venkataraman approach14,17 was not appropriate for
synthesising large amounts of their desired products, since
low yields and product isolation complications were en-
countered in both the benzoylation and condensation
steps.40 In addition, the alternate conditions that had been
developed for directly converting hydroxyacetophenones
into the required diketones (i.e., potassium carbonate,41 or-
ganolithium reagents,42,43 or phase-transfer catalysis44)
proved to be ineffective or impractical for large-scale use.
Therefore, a convenient large-scale preparation of 5-meth-
oxyflavone (40; R1 = 5-OMe, R2 = H) was developed using a
further set of conditions (KOt-Bu, THF, reflux) in the key
step.40
Scheme 9  Alkoxy- and C-glycoside-derived flavones
The developed method was successfully applied to the
convenient synthesis of a number of flavone analogues,
substituted on either aromatic ring, as well as flavones sub-
stituted on both rings. The conditions have also been suc-
cessfully combined with a phenolic alkylation step, thereby
providing a short and efficient means of transforming dihy-
droxyacetophenones into alkoxyflavones.40
Despite the utility of all the known conditions for the
one-step acylation and rearrangement process, the overall
isolated yields tend to be slightly lower than those of the
conventional Baker–Venkataraman sequence (i.e., separate
acylation and migration steps); nevertheless, the method is
practically simple, scalable, quick and efficient.40
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firmly established, there were scant reports of the Baker–
Venkataraman rearrangement used on complex molecules.
Nevertheless, the O-benzoyl ester of C-glycoside 41 (R = H)
was observed to undergo the rearrangement to 1,3-dicar-
bonyl compound 42, a product which was formed as a keto–
enol mixture in 48% yield (Scheme 9, bottom).45 Treatment
of the 42 with trimethylsilyl triflate, at room temperature
in dichloromethane, then yielded the desired C-glycoside
flavone 43.
This approach was extended slightly when it was shown
that the p-anisoyl ester 41 (R = OMe) could also rearrange
when treated with lithium diisopropylamide in tetrahydro-
furan at –35 °C (Scheme 9).45
For a number of decades (1930s–1950s), the exact con-
ditions required for a successful Baker–Venkataraman rear-
rangement to take place and form flavones (44→46) were
investigated by numerous authors (Scheme 10).46 Ultimate-
ly, it was found that, on the substrates studied, sodium
ethoxide in benzene was the best solvent and reagent com-
bination for this reaction. However, from a mechanistic
point of view at least, it was also demonstrated that the re-
arrangement failed in the case of ester 47. Presumably, ow-
ing to the availability of an additional acidic proton in this
substrate, a competing enolate (i.e., 49) can be formed upon
reaction with base, therefore, once formed, the enolate de-
rived from the methyl ketone will not attack the enolate of
the α,α-diphenyl ester due to charge repulsion. In addition,
the α,α-diphenyl ester is large and may be too sterically
hindered to react.
The Baker–Venkataraman rearrangement has also been
used as a key step in the synthesis of trihydroxyflavanones
5147 as well as isoflavones 5448 (Scheme 11).
Other examples of the Baker–Venkataraman rearrange-
ment, that offer the rearranged 1,3-diketone products di-
rectly from the acetophenone starting material, are those
published by Seshadri and Gupta in 1957. In their work, 2′-
hydroxyacetophenone (55) and aroyl chlorides were heated
to reflux in acetone containing anhydrous potassium car-
bonate, to give the dibenzoylmethane products 56 directly.
These were subsequently cyclized to flavones 57 in good
yields (Scheme 12).49 However, this simplified procedure
was reported to have its limitations, whereby 2′-hydroxy-
4′,6′-dimethoxyacetophenone (58, R = H) and 2′-hydroxy-
3′-methyl-4′,6′-dimethoxyacetophenone (58, R = Me) failed
to undergo conversion into the corresponding dibenzoyl-
Scheme 10  Limitations of the early Baker–Venkataraman rearrangement
O
O
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R
45 39–41%
OH O O
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O
R
44 R = 2-Me, 3-Me, 4-Me
OO
O
Ph
Ph
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OH O O
Ph
Ph
46
48
H2SO4
OO
O
Ph
Ph
49
Scheme 11  The synthesis of trihydroxyflavanones (51) and isoflavones (54)
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l.methanes 60 (Scheme 12).44 The lack of reactivity of these
acetophenones was attributed to the resonance effect of the
methoxy groups deactivating the ketone to enolate forma-
tion (58↔59), an effect which has been reported on similar
substrates in the mechanisticallyrelated Truce–Smiles rear-
rangement.50
Later, research published in 1982 by Makrandi and co-
workers presented a related process which was able to
overcome the limitation above, in which an extremely facile
one-step procedure was developed. They found that, when
the 2′-hydroxyacetophenone starting materials 61, contain-
ing either methoxy or methyl groups at various positions,
were subjected to reaction with an aroyl chloride 62 and ei-
ther aqueous potassium carbonate or potassium hydroxide
solution, in benzene, under phase-transfer-catalysis condi-
tions (n-tetrabutylammonium hydrogen sulfate), the reac-
tion resulted in the formation of the corresponding diben-
zoylmethanes in near quantitative yields.44 The benzene
solution, upon treatment with p-toluenesulfonic acid, then
afforded cyclized flavones 63 in excellent yields (Scheme
13). The method was of general applicability, and even 2′-
hydroxy-4′,6′-dimethoxyacetophenones and 2′-hydroxy-3′-
methyl-4′,6′-dimethyoxyacetophenones 58 were found to
undergo smooth conversion under these amended condi-
tions.44
With their newly developed conditions, the authors
were able to use this modified Baker–Venkataraman rear-
rangement to synthesize a variety of hydroxyflavones too.51
Finally, in an approach towards the synthesis of a novel
class of antihypertensive agents with catecholamine-
depleting properties [e.g., flavodilol (67) and its analogues
68], Wu et al. demonstrated that the modified Seshadri pro-
tocol49 (potassium carbonate in refluxing acetone) could of-
fer the key diketone intermediate 65 directly, which, fol-
lowing cyclization, afforded the desired 7-hydroxyflavone
66 in good yield (85%), ready for further manipulation to 67
and 68 (Scheme 14).41
4.2 Xanthones
Xanthones are a particular class of oxygenated hetero-
cycle that occur widely as secondary metabolites in some
higher plant families, such as gentianaceae, guttiferae, fungi
and lichens.52 These natural derivatives are found with
Scheme 12  Deactivated substrates
Ar
OOOOH OH
acetone, Δ
Ar
OOOOH OH
MeO OMe MeO OMe
OOH
OMeMeO
R RR
55 56
58 R = H, Me
ArCOCl, K2CO3
59 60
ArCOCl
57
O
O
ArH
Scheme 13  Phase-transfer-catalyzed rearrangements
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Scheme 14  Synthesis of a novel class of antihypertensive agent
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with methoxy, hydroxyl and glycosyl groups being the most
frequently occurring.53,54
The pharmacological properties of both natural and
synthetic xanthone derivatives have been reported exten-
sively in the literature, reflecting the growing interest in
this class of compound.55 These properties include antial-
lergic,56 antifungal,57 anti-inflammatory,58 antimalarial,59
and antitumor activities,60 as well as antioxidant behavior,61
and there are currently two formulations of oxygenated
and prenylated xanthones on the market being used as anti-
oxidants.62 The aromatic character and the presence of hy-
droxyl groups and/or catechol moieties at certain positions
of the xanthone core appear to be crucial requirements for
strong antioxidant activity to exist.58
Investigations by Silva and co-workers led to an exten-
sion of the substrate scope of the Baker–Venkataraman re-
arrangement to include precursors that contain α,β-unsatu-
rated esters. The authors demonstrated an efficient and
general route towards the synthesis of hydroxylated 2,3-di-
arylxanthones 73, in which the key intermediate of this
synthesis (3-bromo-2-styrylchromone 72), is obtained via a
Baker–Venkataraman rearrangement of the appropriate 2′-
cinnamoyloxyacetophenone 70 (Scheme 15).63 The key step
consisted of a cinnamoyl group transposition from the phe-
nyl 2-position to the acetyl group’s methyl carbon (70→71).
The reaction was performed by treatment of 70 with potas-
sium hydroxide in dimethylsulfoxide to afford 5-aryl-3-hy-
droxy-1-(2-hydroxyphenyl)penta-2,4-dien-1-ones 71 in
good yields (73–95%); products 71 were then cyclized into
the desired 3-bromo-2-styrylchromones 72 (53–67%). After
two more steps, the hydroxylated 2,3-diarylxanthones 73
were obtained in good yields (70–94%).63
4.3 Chromones
Chromones are one of the most abundant classes of nat-
urally occurring oxygen heterocycles,64 and they are found
in a wide variety of synthetic products as well. The signifi-
cance of these compounds is due not only to the important
biological functions they play in nature, but also because
certain derivatives have shown considerable pharmacologi-
cal, biocidal, antioxidant,64 anticancer,65–67 anticardiovascu-
lar,68 and anti-inflammatory activities.69 Some of the more
successful candidates are also marketed as drugs.70
Their interest in the synthesis of biologically active
compounds with heterocyclic skeletons, especially polyhy-
droxy-2-styrylchromones, led Pinto et al. to develop a sim-
ple and successful research program that was aimed at the
synthesis of (E,E)-3-cinnamoyl-5-hydroxy-2-styrylchro-
mones 75 (Scheme 16).71
During their research, in efforts to both utilize inexpen-
sive reagents and create shorter reaction times, they ap-
plied a two-step approach, namely, double esterification
of the appropriate 2,6-dihydroxyacetophenone with
cinnamoyl chloride derivatives, followed by the Baker–
Venkataraman rearrangement of the resulting (2E,2′E)-2-
acetyl-1,3-phenylene bis(3-phenylacrylate)s 74 in 86%
yield.72 In the event, great improvements in the yield of the
rearrangement were achieved when microwave irradiation
(400 W) was used (Scheme 16),32 whilst the notable benefi-
cial effects of using microwave irradiation also saw the
shortening of the reaction time from 1 hour to 17 minutes.
Other work in this area includes Nishinaga and co-
workers successfully achieving the synthesis of ten differ-
ent chromone derivatives through a process involving a
Baker–Venkataraman rearrangement followed by cycliza-
tion promoted by a metal complex.73 In their approach, the
Scheme 15  The synthesis of xanthones
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l.rearrangement products 78 were prepared conveniently by
the potassium tert-butoxide induced Baker–Venkataraman
rearrangement of 2′-acyloxyacetophenones 77 in N,N-di-
methylformamide at room temperature in good yields (54–
89%). The 1-(2-hydroxyaryl)-1,3-diketones 78 were subse-
quently cyclized in methanol, or trifluoroethanol, contain-
ing a cobalt(salen) complex [CoIII(salpr)(OH)]74 at 60 °C, to
offer the chromones 79 in 70–100% yields (Scheme 17).73
Other chromones, less widely occurring in nature, also
exhibit important biological activities. For example, 2-sty-
rylchromones have shown potent in vitro cytotoxicity
against human leukaemia cells.75,76 Prior to the isolation of
these natural 2-styrylchromones, studies had been carried
out on numerous structurally related synthetic analogues
that also showed promising antitumor and antiallergic ac-
tivities.77 Moreover, it was demonstrated by Desideri et al.
that certain synthetic derivatives are inhibitors of replica-
tion of the human anti-rhinovirus,78 while other authors
have found that 3′-allyl-5,7,4′-trimethoxy-2-styrylchro-
mone inhibits oxidative phosphorylation,79 and that hy-
droxy-substituted 2-styrylchromones also act as potent
xanthine oxidase inhibitors.80
Based on these precedents, Silva and co-workers pre-
pared several hydroxy-2-styrylchromone derivatives 84 by
the Baker–Venkataraman method,81 in which the transfor-
mation of compounds 82 into 5-aryl-3-hydroxy-1-(2-hy-
droxyaryl)penta-2,4-dien-1-ones 83 was carried out by
treatment with an excess of potassium hydroxide in di-
methylsulfoxide (Scheme 18). Compound 83 was subjected
to cyclodehydration to offer the corresponding benzyloxy-
substituted 2-styrylchromones 84, whilst subsequent de-
benzylation of 84 was achieved by treatment with a solu-
tion of hydrogen bromide in acetic acid at reflux, to give the
corresponding hydroxy-substituted 2-styrylchromones in
moderate yields.
Similar rearrangements to those shown in Schemes 17
and 18 have also been carried out under solvent-free condi-
tions, where the authors employed a solid-phase grinding
of reagents to accomplish the Baker–Venkataraman reac-
tion.82
Further applications of the Baker–Venkataraman rear-
rangement in the formation of chromones include exam-
ples that combine oxidative or acidic catalytic cycliza-
tion,81,83,84 conditions which have been exploited by Bu and
co-workers (Scheme 19).85 For example, in their search for
potent anticancer molecules, these researchers developed
an efficient one-pot synthesis of multifunctionalized
chromeno[2,3-c]pyrrol-9(2H)-ones 87.85 Their process real-
izes the synthesis of 1,3-diaryl-1,3-diketones 86 from aro-
matic esters 85 via a Baker–Venkataraman rearrangement
(K2CO3 in pyridine at 75 °C), in good yields (70–83%).85 The
β-diketone intermediates 86 were esterified with various
protected amino acids (lysine, aspartic acid, alanine, leu-
cine, phenylalanine, tyrosine, and methionine) to offer the
final products, 1,3-substituted chromeno[2,3-c]pyrrol-
9(2H)-ones 87, in 44–89% yields, a sequence which involves
a second Baker–Venkataraman rearrangement (Scheme
20).85 Under these conditions the method was successful in
increasing the substrate diversity of the Baker–Venkataraman
rearrangement towards this valued product class.
Scheme 16  The synthesis of chromones
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Scheme 17  The synthesis of chromone derivatives
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86 involves two steps, one of which is a second Baker–
Venkataraman rearrangement (Scheme 20). Firstly, a 4-di-
methylaminopyridine-catalyzed Baker–Venkataraman rear-
rangement occurs immediately after the esterification of 86
with the amino acid, giving the chromone intermediate 90.
Secondly, the 9-fluorenylmethyloxycarbonyl (Fmoc) group
is removed by 4-dimethylaminopyridine under the same
conditions.86 The liberated amino group of 91 then under-
goes intramolecular attack of the proximal carbonyl which
is followed by elimination to afford the final products 87.85
4.4 Coumarins
Coumarin (2H-1-benzopyran-2-one) is a plant-derived
natural product that possesses an assortment of pharmaco-
logical activities, including anti-inflammatory,87 antifun-
gal,88 antimicrobial89 and anti-HIV activities.90 Further-
more, examples of isolated naturally occurring coumarins
(specifically, dicoumarol and umbelliferone) are well
known for their anticoagulant properties.91 Given their im-
portance, Snieckus and co-workers documented a novel
and general method for the synthesis of substituted 4-hy-
Scheme 18  Hydroxy-substituted 2-styrylchromone derivatives
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Scheme 19  A heterocyclic Baker–Venkataraman rearrangement
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Scheme 20  A sequential Baker–Venkataraman rearrangement on rearrangement product 86
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l.droxycoumarins 97 (10 derivatives in 79–95% overall yields)
using his carbamoyl variant of the Baker–Venkataraman re-
arrangement (Scheme 21).92
This was the first major variant of the Baker–Venkataraman
rearrangement and was reported in 1998.92 In it, ortho-acyl
arylcarbamates 93 are rapidly and efficiently converted
into substituted 4-hydroxycoumarins 97, a large and highly
diverse class of natural products that exhibits a broad spec-
trum of biological activity.93–95 Furthermore, the authors
demonstrated the application of this carbamoyl Baker–
Venkataraman strategy to the construction of a putative
coumarin natural product and provided its structural revi-
sion.92
In their prototype study of the Baker–Venkataraman re-
arrangement on 93 (Scheme 21), an exploration of condi-
tions gave varying results (LDA, THF, 0 °C: complex mix-
ture; LDA, toluene, r.t.: 54% yield; BrMgN(i-Pr)2, toluene, r.t.
to 70 °C: 62% yield; K2CO3, 18-crown-6, toluene, reflux: no
reaction). However, sodium hydride was found to be effec-
tive in several solvents, such that 2.5 equivalents of sodium
hydride in tetrahydrofuran, toluene or xylene (at 0.2 M) at
reflux for approximately two hours were the optimal condi-
tions to afford 2-hydroxyarylacetamide 94 in high yield,
and whose subsequent conversion into 97 was effected
smoothly with trifluoroacetic acid (3 equiv) in refluxing
toluene at 0.25 M concentration.92
The absence of side products in this carbamoyl migra-
tion reaction, even at relatively high (0.2 M) concentrations,
suggests that, as demonstrated in the ester Baker–
Venkataraman equivalent,96 an intramolecular mechanism
is taking place. For this reason, this route is regarded as a
convenient, efficient approach to 4-hydroxycoumarins 97
that has particular preparative advantages in that 3-aryl- or
3-alkyl-substituted coumarins are obtained directly.92
Using this strategy, the authors further demonstrated
the total synthesis of 4,6-dimethoxy-3,7-dimethylcouma-
rin (98), the putative natural product isolated from Colchi-
cum decaisnei, and isoeugenetin methyl ether (99, R = Me),
a synthetic derivative of isoeugenetin (99, R = H), isolated
from Eugenia carvophyllata, as well as a variety of the cou-
marins exemplified by the general structure 97 (Scheme
21).97
4.5 Anthrapyran and Anthracyclin Antibiotics
Indomycinones98 (Figure 3) belong to the anthrapyran
antibiotic family and occur mainly as their C-glycosides
(e.g., pluramycines, hedamycines, riboflavines, altromy-
cines and indomycines).99,100 Due to their selective binding
to DNA and their specific alkylation of guanine,101,102 they
have been the focus of renewed interest in the context of
structural biology.103 Additionally, a number of aglycones
with the anthra[b]pyran nucleus have also been found in
nature. For example, β-indomycinone [100,
R1 = C(OH)(Me)C4H7, R2 = Me]104 and δ-indomycinone [100,
R1 = C(OH)(Me)C4H9O, R2 = Me]104 have a six-carbon side
chain at C-2, while γ-indomycinone [100,
R1 = C(OH)(Me)C2H5, R2 = Me],98 kidamycinone [100,
R1 = C(Me)=CHMe, R2 = Me],105 the anti-hepatitic antibiotic
AH-1763 IIa [100, R1 = CH(Me)C3H7, R2 = Me], and the neu-
roprotective espicufolin [100, R1 = CH(Me)C2H5, R2 = Et]
have a four-carbon side chain.106 Recently, several research-
ers have attempted the synthesis of espicufolin [100,
R1 = CH(Me)C2H5, R2 = CH2OH],107,108 kidamycinone,109 and
AH-1763 IIa,106 and this remarkable interest is attributed to
their potent biological properties.
Figure 3  The synthesis of anthrapyran antibiotics
Scheme 21  The synthesis of coumarins and isoeugenetin methyl ether (99)
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l.In one approach by Krohn et al. towards the synthesis of
(±)-γ-indomycinones, the Baker–Venkataraman rearrange-
ment was employed as a chain-elongation strategy to avoid
the often necessary reduction and/or oxidation steps con-
nected with the typically utilised organometallic reactions
on the anthraquinone skeleton to achieve this transforma-
tion.110,111 The key Baker–Venkataraman rearrangement
was induced by heating ester 101 at reflux in tetrahydrofu-
ran with lithium hydride to offer the β-diketo anthraqui-
none 102 in 97% yield (Scheme 22).106 Acid-catalyzed cy-
clization to anthrapyranone 103 gave the carbon skeleton of
the target compound (±)-104, the total synthesis of which
was achieved following further minor elaboration. A similar
protocol was used to prepare the corresponding 11-methyl
ether of γ-indomycinone 104 as well.106
Scheme 22  The synthesis of (±)-γ-indomycinone
In addition, the Baker–Venkataraman reaction has been
widely employed in the synthesis of a large group of an-
thrapyran antibiotics.105,110,112 Similarly, the synthesis of ar-
omatic-polyketide-derived natural products and the biomi-
metic-type synthesis of anthracyclines113 and angucy-
clines114 includes the construction of β-diketo side chains
on an aromatic or quinoid nucleus.115 In efforts to produce
such β-diketo products, Krohn et al. attempted an enantio-
selective acyl-transfer reaction with α-oxygenated esters
under Baker–Venkataraman conditions (Scheme 23).111
In their efforts to achieve this, the base-catalyzed
Baker–Venkataraman rearrangement of (S)-2-acetyl-1-hy-
droxyanthraquinone ester 105 proceeded, with virtually no
racemization, to the β-diketo anthraquinone product (S)-
106 (50%). The subsequent cyclization step offered the en-
antiomerically enriched (>97% ee) anthra[1,2-b]pyran 107,
a close derivative of the neuroprotective compound espicu-
folin (100; Figure 3), in quantitative yield.
Scheme 23  An enantiomerically enriched Baker–Venkataraman rear-
rangement
In a related manner, the same reaction procedure was
applied to transform enantiomerically pure O-allyl lactic
ester 108 into anthrapyranone 110 by way of ketide 109
(Scheme 24). The Baker–Venkataraman rearrangement of
ester 108 afforded a 53% yield of (β-diketo)alkyl-substituted
anthraquinone 109 and the cyclization of phenol 109 to 2-
allyloxy-substituted anthrapyranone 110 was excellent
(94% yield), since no cleavage and no isomerization of the
allyl protecting group was observed.111 This model reaction
opened the way to synthesize the enantiomerically pure
10-hydroxyanthrapyranone moiety of the indomycinones,
rubiflavinones 111, pluramycines 112, or hedamycines 113
(Figure 4).100
Scheme 24  The Baker–Venkataraman rearrangement of an O-allyl lac-
tic ester to a ketide
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l.Aklanonic acid 114 (which exists in equilibrium with
the enol form 115 when R = OH) and its derivatives are
starting materials of great interest in studies concerning the
microbial conversion of the antitumor agent aclacinomycin
A (117), since they are suitable precursors for the prepara-
tion of the anthracycline scaffold 116 (Scheme 25).116
Studies on their synthesis by Krohn et al. began with a
Baker–Venkataraman rearrangement (lithium hydride in
tetrahydrofuran) on anthraquinones 118, thus providing a
flexible and general method for the introduction of ketide
side chains on these substrates to produce derivatives 119
in high yield (Scheme 26).113
Moreover, in a similar manner, the attachment of differ-
ent oligoketide side chains to the naphthoquinone nucleus
have been carried out by Krohn and Schafer.117 In such cas-
es, and after a number of trials, they proved that the Baker–
Venkataraman rearrangement of ester 120 was the best
protocol for side-chain elongation (Scheme 27). Sodium hy-
dride in tetrahydrofuran was found to give the best results
for the transformation of 120 into the rearranged product
121 (66% yield); the corresponding naphthoquinone pre-
cursors 121 were then successfully treated with base to ini-
tiate a cascade to yield the 4-deoxyaklanonic acids 122.
Figure 4  Enantiomerically pure 10-hydroxyanthrapyranones
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Scheme 25  Aklanonic acid derivatives
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Scheme 26  Introduction of ketide side chains on anthraquinones
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Benz[b]indeno[2,1-e]pyran-10,11-diones 123–125 (Fig-
ure 5) are known to enhance the biosynthesis of erythro-
poietin, a hematopoietic growth factor which stimulates
differentiation and supports the survival of cells of the
erythroid lineage.118 The methanol extract of the dried
leaves and stems of Wrightia tomentosa revealed weak ac-
tivity against human immunodeficiency virus type 1 re-
verse transcriptase (HIV-1 RT) and Ruchirawat and Thasana
showed that this effect was due to wrightiadione (126),119 a
rare and unusual oxygen heterocycle.120 This finding, and
the reported interesting biological activity of diones 123–
125, motivated the authors to undertake a study of the syn-
thesis of these compounds.121
In their efforts to develop an operationally simple, high-
ly efficient reaction for the synthesis of diones 123–125,
the authors envisaged that benz[b]indeno[2,1-e]pyran-
10,11-dione 125 (isowrightiadione) could be obtained via
the route highlighted by the retrosynthetic analysis in
Scheme 28. It was expected that flavone 127 could be ob-
tained by application of the Baker–Venkataraman rear-
rangement (129→128) followed by cyclization,40,83,122–125
whilst further cyclization would lead directly to the re-
quired compounds 125.121
In the investigation of this route as a practical method
to prepare this class of compound, the acylation of 2-hy-
droxyacetophenone (55) with mono-methyl phthalate
(130), using a Steglich esterification procedure, gave 131 in
68% yield (Scheme 29). The intramolecular Baker–
Venkataraman acylation of 131 was successfully achieved
with potassium hydroxide in pyridine, under reflux for 30
minutes, to give the desired 1,3-diketone 132. Acidification
of a solution of 132/133 then led to the precipitation of the
desired product 125 in 72% yield.121
The elucidated structure of the recrystallized product
was not the expected flavone 127 (R = Me, Scheme 28), but
instead the final target compound 125. The authors ratio-
nalized that the mechanism for the formation of 125 could
involve diketone 132 intramolecularly cyclizing to afford
the 1,3-indanedione 134. Subsequently, the formed he-
miketal 135 could dehydrate to give the obtained product
125 as shown in Scheme 29.121
5 The Retro-Baker–Venkataraman Rear-
rangement
In 1979, Donnelly and Maloney reported that when re-
acted with base, 2-bromo-1,3-diketone 136 formed 2,3-di-
phenylchromone epoxide 139,126 a transformation that sug-
gested an intermediate such as the conjugate base 138.
Scheme 27  Side-chain elongation
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Figure 5  Synthesis of benzopyrans
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Scheme 28  Retrosynthesis of benz[b]indeno[2,1-e]pyran-10,11-diones
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able leaving group (e.g., the bromide ion in 138) fragmenta-
tion may occur to offer 2′-aroyloxyacetophenone 142
(Scheme 30).126
With this in mind, the unbrominated analogue 143 was
treated with potassium carbonate at 0 °C in chloroform to
afford the deoxybenzoin ester 147, via a retro-Baker–
Venkataraman rearrangement (Scheme 31, top).127 When
the 2-phenyl substituent of the 1,3-diketone 143 was ex-
changed for a methyl group (i.e., 149; Scheme 31, bottom),
a retro-Baker–Venkataraman rearrangement also occurred,
though much more slowly. Heating at reflux under the
same reaction conditions for several days gave 2′-benzoyl-
oxypropiophenone (150) in 54% yield, whilst treatment of
the 1,3-diketone 149 with potassium hydroxide at room
temperature afforded the decomposed products, 2′-hy-
droxypropiophenone and propiophenone.127
Moreover, different conditions failed to force diketone
26 to undergo the reverse rearrangement (Scheme 32). It
was thus concluded that the rate of retro-Baker–Venkataraman
rearrangement depends on the 2-substituent of the 1,3-
diketone. A rapid decrease in rate is seen, such that the or-
der of reactivity is Ph > Me > H.127
Scheme 29  Rearrangement of a mono-methyl phthalate derivative
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Scheme 30  A proposed retro-Baker–Venkataraman rearrangement
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Scheme 31  The retro-Baker–Venkataraman rearrangement
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l.Scheme 32  A limitation of the retro reaction
Occupying the 2-position of a propane-1,3-dione with a
hydroxyl group, as in 153, led to retro-Baker–Venkataraman
failure, at least in terms of the isolation of the retro-prod-
uct. Instead, an alternative ester-forming transformation
was demonstrated. For example, reaction of 2-hydroxy-1-
(2-hydroxyphenyl)-3-phenylpropane-1,3-dione (153) with
potassium carbonate offered 2-benzoyloxy-2′-hydroxyace-
tophenone (157), and the mechanism proposed is shown in
Scheme 33 (top).127 Nevertheless, although not considered
originally, we suggest that the retro-transformation
153→158 could occur, but that the aromatic ester produced
(158) is subsequently attacked (i.e., Oaryl → Oalkyl acyl trans-
fer) to give the observed product 157 (Scheme 33, bottom).
Scheme 33  An unexpected rearrangement on a 2-hydroxypropane-
1,3-dione derivative
6 Summary and Outlook
As we hope has become evident from this review, the
introduction to the chemical community in 1910 of a gen-
eral thermal rearrangement of aromatic acyl groups from
oxygen to carbon to generate the corresponding 1,3-dicar-
bonyl compounds has provided an important set of synthet-
ic routes to aromatic heterocycles and other products. The
rearrangement has enjoyed extensive application in both
academic and industrial environments, and it provides gen-
eral routes to the preparation of new medicines and other
molecules of biological interest. Only a couple of examples
of an enantiospecific Baker–Venkataraman rearrangement
are known, and these simply employ enantiopure rear-
rangement precursors which undergo little or no racemiza-
tion during the rearrangement. However, an enantioselec-
tive Baker–Venkataraman rearrangement is yet to be devel-
oped, presumably because of the ready racemization of the
resulting 1,3-dicarbonyl products of the reaction. As such,
there is scope for preparing enantiomerically pure 1,3-di-
carbonyl-bearing quaternary centres using this reaction.
With the importance that is imparted to carbon–carbon
bond-forming reactions, the Baker–Venkataraman rear-
rangement could see an upsurge in its use and development
and thus feature more heavily in synthesis in the future.
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